ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell. Issue 1 (1st December 2015)

• Record Type: Journal Article
• Authors: Liu, Xin; Li, Yajuan; Wen, Liangxue; Tao, Kun; Xiao, Qing; Cao, Weixi; Huang, Zhenglan; Gao, Miao; Li, Hui; Wang, Fang; Feng, Wenli
• Is Part Of: Cancer letters. Volume 369:Issue 1(2016)
• Page Start: 222
• Page End: 228
• Publication Date: 2015-12-01
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2015.08.017
• Languages: English
• ISSNs: 0304-3835

Abstract

<abstract abstract-type="author-highlights" id="ab0010"> <title id="st0010">Highlights</title> <sec> <p id="sp0010"> <list id="ulist0010"> <list-item id="u0010"> <label></label> <p id="p0010">Targeting the interaction of RIN1 and ABL using the ABL SH3 mutant T79Y significantly suppresses leukemia cell growth <italic>in vitro</italic>.</p> </list-item> <list-item id="u9010"> <label></label> <p id="p9010">ABL SH3 mutant T79Y markedly repressed the expression of BCR-ABL signaling pathways.</p> </list-item> <list-item id="u0015"> <label></label> <p id="p0015">Combination of ABL SH3 mutant T79Y potentiates the efficacy of IM <italic>in vitro</italic> and <italic>in vivo</italic>.</p> </list-item> </list> </p> </sec> </abstract>